RxDoctor Payments Data

Manisha Nidamarthy

Primary Care · Camden, NJNPI 1366176398

Payments from drug & device makers

$1,520in general payments, 2019–2025

Across 63 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$323
  • AstraZeneca$255
  • AbbVie$208
  • Pfizer$136
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$134
  • Lilly USA, LLC$110
  • plus $354 from 10 others

What the payments were for

  • Food & beverage$1,520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,520 in reported general payments places this provider in the 70th percentile of 330 primary care providers in New Jersey.

See all primary care providers in New Jersey

Medicare billing

Part B allowed, 2024
$8,627
Medicare patients
72
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin28$24,217
JanuviaSitagliptin Phosphate20$16,568
EliquisApixaban22$12,976
FarxigaDapagliflozin Propanediol15$11,711
Breo ElliptaFluticasone/Vilanterol17$6,788
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,787
Albuterol Sulfate HfaAlbuterol Sulfate128$3,033
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,153
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$1,760
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,463
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm12$1,351
Atorvastatin Calcium158$1,293
Levetiracetam19$758
Rosuvastatin Calcium30$675
Fluticasone Propionate43$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$15$16,56820 claims
PfizerEliquis$136$12,97622 claims
AstraZenecaFarxiga$255$11,71115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 330 primary care providers in New Jersey.

Other primary care in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →